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INTRODUCTION
Granulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (PBSCs) from healthy donors
have been used in place of bone marrow (BM) in adult allo-
geneic hematopoietic stem cell transplantation [1]. There are
practical advantages to using PBSCs rather than BM as a
stem cell source, including rapid hematopoietic reconstitu-
tion, fewer infectious complications, and possible enhance-
ment of the graft-versus-leukemia (GVL) effect [2-5]. The
beneﬁt of PBSCs for donors is elimination of the need for
general anesthesia and hospitalization associated with BM
aspiration. However, in children, technical difficulties of
PBSC harvest by apheresis, such as overcoming the problems
of extracorporeal volume and blood access [6] and a concern
for the use of G-CSF in healthy children, have restricted the
use of PBSCs in the allogeneic setting [7,8]. Although safe
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ABSTRACT
Allogeneic peripheral blood stem cell transplantation (PBSCT) was performed in children and adolescents for the
treatment of malignant (n = 49) and nonmalignant hematological disease (n = 8). Granulocyte colony-stimulating
factor (G-CSF)–mobilized PBSCs were apheresed from 57 HLA-matched siblings aged 9 months to 24 years
(median, 8 years) without any serious adverse effects. No abnormalities were found in these donors for a median fol-
low-up of 25 months (range, 6-56 months). Patients were conditioned with a TBI-containing regimen (n = 17) or a
non-TBI regimen (n = 40). GVHD prophylaxis consisted of methotrexate (MTX) plus cyclosporine A (CSP) for
23 patients, CSP plus methylprednisolone (mPDN) for 22 patients, MTX only for 7 patients, CSP only for 4 patients,
and MTX plus CSP plus mPDN for 1 patient. Engraftment was prompt, with a median number of days to reach an
absolute neutrophil count (ANC) above 0.5 × 109/L of 13 days (range, 8-23 days), with 1 graft failure. Acute GVHD
(grades II-IV) occurred in 8 (16%) of 49 evaluable patients, and chronic GVHD developed in 23 (64%) of 36 evalu-
able patients. Notably, two thirds of chronic GVHD was extensive. The Kaplan-Meier estimate of 3-year disease-
free survival was 0% for refractory disease (n = 6), 37.2% ±11.8% for high-risk malignancies (n = 25), 81.4% ±9.7%
for standard-risk malignancies (n = 18), and 100% for nonmalignant disease (n = 8). The estimated 100-day nonre-
lapse mortality rate was 9.9% ±4.2%. In conclusion, allogeneic PBSCT is feasible in a pediatric population.
Although the grade of acute GVHD was set low, as in Japanese BMT studies, the incidence and severity of chronic
GVHD appears to be relatively high. For nonmalignant disease, the question arises of whether the higher incidence
and severity of chronic GVHD is a drawback of this procedure. For high-risk malignancies, whether or not a graft-
versus-leukemia effect prevents relapse needs to be clarified in future comparative studies with BMT.
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and effective PBSC harvesting procedures have been demon-
strated in the autologous setting [9,10], we should be more
careful with normal donors, and the long-term toxicities of
G-CSF treatment must be carefully assessed.
In the present report, we describe our experience with
allogeneic PBSC transplantation (PBSCT) in pediatric
patients with HLA-matched sibling donors. Although this
study was hampered by differences in the approaches used at
10 different institutions with regard to PBSC collection
methods, preparative regimens, and supportive care issues,
we believe that the observed data may still be useful for
assessing the value of this procedure in pediatric patients.
METHODS
Patients and Donors
The characteristics of the patients and donors are shown
in Table 1. The clinical protocols for PBSCT were approved
by the institutional review boards at the participating insti-
tutions. Patients were eligible for enrollment if allogeneic
stem cell transplantation was indicated for their disease and
they had an HLA-identical sibling. Written informed con-
sent was obtained from the patient’s guardian (or the patient
if he/she was more than 16 years old). Before stem cell col-
lection, the details of the procedure and risks of both BM
harvest and PBSC collection were fully explained. The deci-
sion to agree to PBSC harvest was made by the donor’s
guardian alone (if the donor was less than 10 years old), by
both the donor’s guardian and the donor (if more than 10
but less than 16 years old), or by the donor alone (if more
than 16 years old), and written informed consent was
obtained. This choice was based on the medical condition
of the donor in 18 transplantations or the medical condition
of the patient in 32 transplantations. For the remaining
7 donors, PBSC harvest was the donor’s preference. The med-
ical conditions of the donors included the risks associated
with the use of general anesthesia such as bronchial asthma
(n = 12), difﬁculties in BM harvest such as obesity (n = 4), or
body weight differences between the donor and the patient
(n = 2). The medical conditions of the patients included the
anticipation of rapid engraftment after allogeneic PBSCT
because the patients were at high risk for life-threatening
infection (n = 7), and the anticipation of possible GVL
effects for high-risk malignancies or second transplantations
(n = 15). In the remaining 10 cases, the physician’s prefer-
ence was the only reason for the choice of PBSC.
PBSC Harvest
All of the donors received G-CSF at a dosage of 7.5 to
10 µg/kg per day by subcutaneous injection for 5 to 6 days.
On days 4 and 5 or 5 and 6 of G-CSF treatment, donors
underwent apheresis using continuous blood cell separators
(Baxter CS3000 Plus: n = 29; COBE Spectra: n = 28). For
12 donors weighing less than 20 kg, the extracorporeal cir-
cuit was preprimed with 75 to 200 mL of autologous blood
or allogeneic irradiated leukocyte-depleted packed red
blood cells, depending on the machine and separating cham-
ber. For blood access, a radial artery was used in 35 donors
(mostly less than 10 years old) and a cubital vein was used in
14 donors (10 years old or more). Eight donors had central
venous (CV) catheter placement (inguinal, 5; subclavian, 3)
if peripheral blood access was not achieved. Ketamine was
used to sedate donors when a CV catheter was inserted,
whereas no sedation was used when a radial artery or a
cubital vein was accessed in donors, except in 3 donors. The
target volume of processed blood per apheresis was 200 to
300 mL/kg for children and 10 L for adolescents. PBSCs
from 52 donors were frozen using a programmed freezer (n = 3)
or an uncontrolled method without a programmed freezer
as described elsewhere (n = 49) [11]; and they were stored in
a deep freezer (n = 33) or the vapor phase of liquid nitrogen
(n = 19) until transplantation according to each institution’s
protocol. PBSCs from 5 donors were infused without freez-
ing on day 0. T cells were not depleted from any of the
grafts. For cell evaluation, CD34+ and CD3+ cells were ana-
lyzed by ﬂow cytometry, and colony-forming units–granulo-
cyte/macrophage (CFU-GM) were analyzed by in vitro
colony assay at each institution.
Donors were followed up every 6 months or 1 year for
blood counts and a medical check-up.
Transplantation Procedures
Preparative regimens and graft-versus-host disease
(GVHD) prophylaxis are shown in Table 2. The diagnosis of
GVHD was based mainly on clinical symptoms, and if the
diagnosis was in doubt, a biopsy was performed. The grades of
GVHD were determined according to 1994 Consensus Con-
ference criteria [12]. Cyclosporine A (CSP) was tapered begin-
ning 60 to 100 days following transplantation and was reduced
by 10% per week in most cases if no GVHD was observed.
Statistical Methods
The date of ﬁnal analysis was December 31, 2000. The
time required to attain an absolute neutrophil count (ANC)
of at least 0.5 × 109/L or a platelet count of at least 20 ×
109/L without platelet transfusion was calculated using the
Kaplan-Meier method [13]. Overall survival and disease-free
Table 1. Patient and Donor Characteristics
Patients (n = 57) Donors (n = 57)
Median age (range) 10 y (6 mo to 19 y) 8 y (9 mo to 24 y)
Sex, M/F 28/29 31/26
Median body weight, kg (range) 29 (5-71) 31 (9-70)
Disease
Malignancy 49
ALL 23
First CR 4
Second CR 6
Third or more CR 10
Refractory 3
AML 18
First CR 8
Second or more CR 10
Refractory 2
CML 1
MDS 3
Non-Hodgkin’s Lymphoma 4
Nonmalignancy 8
Severe aplastic anemia 6
Chronic granulomatous disease 1
Kostmann’s disease 1
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survival were calculated using Kaplan-Meier methods and
evaluated using the log-rank test with 95% confidence
interval (CI). Disease-free survival was calculated from date
of transplantation to date of relapse or death by any cause if
there was no relapse.
RESULTS
Mobilization and Collection of PBSCs
During G-CSF treatment, 7 donors (17.5%), most older
than 10 years, complained of lumbago or bone pain, and
3 donors (5.3%) complained of headache, which was relieved
by nonsteroidal anti-inflammatory agents. Although very
young children could not complain, they appeared to be ﬁne
during G-CSF treatment. Only 1 donor had a very high
white blood cell count (72.0 × 109/L), and the dose of G-CSF
was reduced. The procedure for PBSC harvest was well tol-
erated, and neither hemodynamic instability, clinical evi-
dence of severe hypocalcemia, nor vaso-vagal reflex was
noted during PBSC collection. Mild hypocalcemia was
observed in 10 donors and relieved with an increased infu-
sion of calcium gluconate. The average number of aphereses
was 2 (range, 1-4), and an average of 480 mL/kg (range, 212-
1266 mL/kg) of blood was processed. The platelet count
decreased in all of the donors, falling to less than 100 × 109/L
in 51 donors (89.5%) and less than 50 × 109/L in 6 donors
(10.5%). However, there was no clinically signiﬁcant bleed-
ing, and platelet counts returned to the normal range within
7 to 10 days after the last apheresis. This decrease in the
platelet count became prominent following multiple aphere-
ses, and 6 donors required reinfusion of their own platelet-
rich plasma, which was obtained during cell processing.
Forty donors could be followed, and blood examination
showed no abnormalities in any of these donors within a
median follow-up of 25 months (range, 6-56 months).
Engraftment Results
The patients received a median of 8.1 × 108/kg (range,
2.7-16.8) mononuclear cells, 5.2 × 106/kg (range, 1.7-16.9 ×
106/kg) CD34+ cells, 3.6 × 108/kg (range, 1.7-7.1 × 108/kg)
CD3+ cells, and 8.1 (range, 0.4-31.7 × 105/kg) CFU-GM. All
of the patients recovered their peripheral blood cell counts,
except for 1 patient with engraftment failure who received
allogeneic PBSCT as a second transplantation after failed
engraftment with BM. The median number (±SE) of days to
an ANC of greater than 0.5 × 109/L on 3 consecutive days
was 13.0 ±0.62 days (95% CI, 8-23 days). G-CSF was used
in 27 patients following transplantation. The median number
of days to reach ANC above 500 was 13.1 ±4.2 days (range,
8-18 days) for patients with G-CSF and 14.2 ±3.1 days
(range, 8-23 days) for patients without G-CSF. This differ-
ence was not statistically significant. The median number
of days to a platelet count of greater than 20 × 109/L was
15.0 ±1.04 days (range, 8-115 days). Seven patients did not
reach a platelet count of greater than 50 × 109/L. In the
remaining 42 patients, the median number of days to a
platelet count of greater than 50 × 109/L was 17 days (range,
9-49 days). We compared the methotrexate (MTX) group
and the non-MTX group to study the effect of MTX, which
was used for GVHD prophylaxis, on engraftment. The
median number of days to reach an ANC above 500 was
14.2 ± 3.1 for the MTX group and 11.0 ± 2.3 for the non-
MTX group (P = .0049). Thus, the use of MTX signiﬁcantly
affected engraftment.
Graft-Versus-Host Disease
Forty-nine patients who survived more than 60 days
were evaluable for acute GVHD, and 36 patients who sur-
vived 100 days or more were evaluable for chronic GVHD
(Table 3). Eight patients (16.3%) showed clinical grade II to
IV acute GVHD, and 1 patient died because of acute
Table 2. Preparative Regimens and GVHD Prophylaxis*
Preparative regimens (n = 57)
Malignant disease (n = 49) Nonmalignant disease (n = 8) GVHD prophylaxis (n = 57)
TBI-containing regimen 15 TBI-containing regimen 2 CSP plus MTX 23
Plus CY/VP-16 5 Plus CY 1 CSP plus mPDN 22
Plus CY/Ara-C 3 Plus CY/ALG 1 MTX only 7
Plus L-PAM 2 Non-TBI regimen 6 CSP only 4
Plus CY 1 CY/ATG 2 CSP/MTX/mPDN 1
Plus Ara-C 1 Bu/CY 1
Plus L-PAM/VP-16 1 Bu/CY/TLI 1
Plus L-PAM/Ara-c 1 CY/TLI 1
Plus Bu/L-PAM 1 CY/TLI/ALG 1
Non-TBI regimen 34
Bu/L-PAM 18
Bu/CY 6
MCVAC 3
Bu/Ara-C/VP-16 2
Bu/CY/TEPA 1
CY/TEPA 1
Bu/MCNU/CY 1
Bu/TEPA 1
VP-16/TEPA/CBDCA 1
*TBI indicates total body irradiation; mPDN, methylprednisolone; CY, cyclophosphamide; VP-16, etoposide; Ara-C, cytosine arabinoside;
ALG, antilymphocyte globulin; L-PAM, melphalan; ATG, antithymocyte globulin; Bu, busulfan; TLI, total lymphoid irradiation; MCVAC,
MCNU plus cytosine arabinoside plus etoposide plus cyclophosphamide; TEPA, thiotepa; CBDCA, carboplatinum.
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GVHD-associated infection. In 36 evaluable patients,
chronic GVHD developed in 23 patients (64%). Seventeen
patients had extensive forms, involving the oral mucosa, eyes,
upper gastrointestinal tract, liver, and lung. Two patients
showed clinical symptoms and findings similar to those of
systemic sclerosis. Three patients died from progressive lung
disease probably related to chronic GVHD. A higher dose of
prednisolone or methylprednisolone was used to control
acute GVHD in all cases. Various immunosuppressive
agents, including steroids, FK 506, azathiopurine, and anti-
lymphocyte globulin, were used to control chronic GVHD.
Outcomes and Survival
Nine patients (15.8%) relapsed or exhibited refractory
disease during this study (Table 4). Thirteen patients (22.8%)
died from transplantation-related toxicities. Transplantation-
related toxicities included GVHD or associated complica-
tions (n = 4), infection (n = 3), pulmonary toxicity (n = 3),
veno-occlusive disease of the liver (n = 2), intracranial bleed-
ing (n = 1), and graft failure (n = 1). Deaths related to trans-
plantation-related complications occurred 26, 30, 39, 48, 49,
54, 65, 90, 140, 195, 235, 248, and 539 days following trans-
plantation. The estimated 100-day nonrelapse mortality rate
was 9.9% (95% CI, 5.7%-14.1%). Survival was assessed
according to 4 groups (Figure 1): high-risk hematological
malignancy, standard-risk hematological malignancy, refrac-
tory malignant disease, and nonmalignancy. The ﬁrst cate-
gory included transplantations following the second or more
complete remission (CR) of acute myelogenous leukemia
(AML) or the third or more CR of acute lymphoblastic
leukemia (ALL); high-risk myelodysplastic syndrome
(MDS) (refractory anemia with excess blasts); and chronic
myelogenous leukemia (CML) in blastic crisis (n = 25). The
second category included hematological malignancies fol-
lowing the ﬁrst CR of AML or ﬁrst or second CR of ALL
and low-risk MDS (refractory anemia) (n = 18). The risk
features that allowed patients to undergo allogeneic trans-
plantation in the first CR included Philadelphia chromo-
some- or MLL-positive or infant ALL or AML except AML
with t(8,21) and inv. 16. The third category included trans-
plantations at relapse or refractory disease (n = 6). The
fourth category included severe aplastic anemia (n = 6),
chronic granulomatous disease (n = 1), and Kostmann’s dis-
ease (n = 1). The Kaplan-Meier estimate of 3-year overall
Table 3. Graft-Versus-Host Disease
n (%)
Acute GVHD 49
Grade 0 28 (57)
Grade I 13 (27)
Grade II 5 (10)
Grade III 1 (2)
Grade IV 2 (4)
Grades II-IV 8 (16)
Grades III-IV 3 (6)
Chronic GVHD (n = 36) 23 (64)
Limited 6 (26)
Extensive 17 (74)
Organs involved
Oral mucosa 20 (56)
Skin 15 (42)
Eyes 10 (28)
Lungs 6 (17)
Liver 4 (11)
Gastrointestinal tract 3 (8)
Table 4. Causes of Failure for Malignant Disease
Standard
Refractory High Risk Risk
(n = 6) (n = 13) (n = 3)
Refractory disease 2
Relapse 3 2 2
GVHD 4
Acute 1
Chronic 3
Transplantation-related toxicity 1 7 1
Infection 1 2
Veno-occlusive disease 2
Pulmonary 3 1
Bleeding 1
Graft failure 1
Figure 1. Overall survival (A) and disease-free survival (B) for hemato-
logical malignancies. Overall survival and disease-free survival were
assessed according to 3 categories: high-risk hematological malignan-
cies, standard-risk hematological malignancies, and refractory malig-
nant disease.
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survival was 37.6% (95% CI, 26.0%-49.2%) for high-risk
malignancies, 78.4% (95% CI, 66.8%-90.0%) for standard-
risk malignancies, and 16.7% (95% CI, 0.5%-31.9%) for
refractory malignant disease. The Kaplan-Meier estimate of
3-year disease-free survival was 37.2% (95% CI, 25.4%-
59.0%) for high-risk malignancies, 81.4% (95% CI, 71.7%-
91.1%) for standard-risk malignancies, and 0% for refractory
malignant disease. All of the patients with nonmalignant dis-
ease have been alive and disease-free for a median of 1112 days
(range, 356-1908 days; data not shown).
We also analyzed the relationship between chronic
GVHD and overall survival for 35 evaluable patients with
malignancies. There was a trend toward increased survival
in patients with chronic GVHD compared to those without
GVHD, although this difference was not statistically signiﬁ-
cant (P = .088) (Figure 2). In addition, only 3 of 23 patients
with GVHD developed relapse, whereas 4 of 14 patients
without GVHD relapsed. Again, this difference was not sta-
tistically signiﬁcant.
DISCUSSION
When PBSCs are collected from pediatric donors, 2 major
issues should be considered: the short-term and long-term
effects of G-CSF on normal children and the safety of PBSC
harvest procedures. The results of this study suggest that the
collection of PBSCs from pediatric donors is feasible with
acceptable adverse effects, although the long-term effects of
G-CSF administration should be monitored for a longer
period. Although G-CSF has a theoretical risk of clonal evo-
lution [14], no adverse clinical or hematological events have
occurred with, at most, a 5-year follow-up in a limited num-
ber of donors [15,16]. For a safe apheresis procedure, prob-
lems associated with extracorporeal blood volume, blood
access, hypocalcemia due to acid-citrate-dextrose solution A
(ACD-A) toxicity (anticoagulant), and the vago-vagal reﬂex
should be overcome. For blood access to obtain sufficient
blood ﬂow, placement of a CV line may not be justiﬁed in
this donor population. Placement of CV catheters is accom-
panied by serious complications such as pneumothorax, per-
foration of the superior vena cava, and venous thrombosis
[17,18]. Further, placement of a CV catheter requires general
anesthesia in small children. Thus, peripheral blood access
should be used. In children weighing less than 20 kg, the cell
separator must be primed with blood to avoid circulatory
collapse, and autologous blood must be used to avoid the
potential risk of allogeneic blood transfusion [19]. Thus, for
normal pediatric donors, the choice of PBSCs should be
based on these risks and beneﬁts, balanced against the risks
of general anesthesia and BM harvesting.
In this study, only 8 of the 49 evaluable patients (16%)
developed grade II to IV acute GVHD. It has been well
documented that both the incidence and severity of GVHD
in Japan are less than those in other countries, because of a
more homogenous distribution of HLA [20]. Thus, the
data are compatible with our historical data. On the other
hand, 23 of 36 evaluable patients (66%) developed chronic
GVHD, mostly extensive forms involving oral mucosa and
skin, whereas this incidence was only 22% in matched-
sibling BMT in our recent report [21]. Five patients suf-
fered from severe chronic GVHD; 3 of them died from
progressive lung disease probably related to chronic
GVHD, and 2 patients showed clinical symptoms and ﬁnd-
ings similar to those of systemic sclerosis, a severe form of
chronic GVHD. Although the grade of acute GVHD was
set low, the incidence and severity of chronic GVHD might
be rather high considering that all of the patients were
Japanese children who received a graft from a matched sib-
ling. This high incidence of chronic GVHD might have
been due to a variety of factors, such as the type of prophy-
laxis against GVHD, the preparative regimen, and the
length of follow-up. In this study, about half of the patients
did not receive MTX for GVHD prophylaxis, consistent
with the widely accepted practice in the Japanese transplan-
tation society. Furthermore, because of high-risk disease
features, strong GVHD prophylaxis might not have been
used in anticipation of GVL effects. Nevertheless, in other
countries it is well recognized that the omission of MTX
contributes to a higher incidence of chronic GVHD [22].
On the other hand, an increased incidence of GVHD may
contribute to a decreased incidence of leukemia relapse by
inducing a GVL effect [23,24], although this issue is still
controversial [25,26]. A limitation of our study was the lack
of a control such as BMT with regard to survival, and we
cannot be certain that allogeneic PBSCT has a greater
GVL effect than BMT. Careful controlled randomized
studies are needed to determine whether PBSCs might
have signiﬁcant GVL effects. Thus, for nonmalignant dis-
ease and standard-risk hematological malignancies, the use
of PBSCs in the pediatric population might be limited
because of a high incidence of chronic GVHD and poor
posttransplantation quality of life, unless the donor’s condi-
tion would support PBSCs [27].
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Figure 2. Overall survival and chronic GVHD. The relationship
between chronic GVHD and overall survival was assessed for 35
patients with hematological malignancies according to the presence
(n = 23) or absence (n = 12) of GVHD.
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